Physician profile
Thomas Sk Chi
NPI 1851341846
$4,916.89
in general payments reported to CMS, 2019-2025
22 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $276 · 2021: $106 · 2022: $583 · 2023: $605 · 2024: $1,256 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,425 · Consulting Fee: $550 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,425.37 |
| Consulting Fee | $550.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,255.56 | 2019-2025 | Clareon, Clareon Panoptix Pro, Lensx |
| Glaukos Corporation | $1,061.92 | 2020-2025 | Idose, Idosetr |
| New World Medical,INC. | $476.32 | 2022-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Abbvie INC. | $472.33 | 2022-2025 | Xen Glaucoma Treatment System, Durysta |
| Allergan, INC. | $339.27 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $221.83 | 2022-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Ivantis, INC | $220.47 | 2019-2020 | |
| Biotissue Holdings INC. | $216.06 | 2023-2025 | |
| Aerie Pharmaceuticals, INC. | $172.48 | 2019 | |
| Sun Pharmaceutical Industries INC. | $112.99 | 2019-2025 | Cequa |
| Rayner Intraocular Lenses Limited | $46.23 | 2024-2025 | Omidria |
| Kala Pharmaceuticals, INC. | $43.06 | 2019 | |
| Omeros Corporation | $41.69 | 2019-2021 | |
| Abb Con-Cise Optical Group LLC | $41.34 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32.12 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $30.49 | 2024 | Omni Surgical System |
| Iridex Corporation | $28.46 | 2019 | |
| Rxsight INC | $28.42 | 2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Ocular Therapeutix, INC. | $21.92 | 2020 | |
| Harrow Eye, LLC | $20.73 | 2025 | Vevye |
| Bausch & Lomb Americas INC. | $17.86 | 2023 | Zenlens, Revive |
| Horizon Therapeutics Plc | $15.34 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Chi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.